Reminders

Changing Life Sciences Value Chain

Archives for February 2011 « Recent Articles

OfflinePhoto of Eric Newmark

This week marked the DIA Marketing Pharmaceuticals 2011 conference, one of the larger annual life science conferences held in the US focused specifically on the pharmaceutical marketing space. The conference included presentations from members of the FDA, multiple pharmaceutical companies, and also included a multitude of workshops for regulatory professionals and promotional review teams.


OfflinePhoto of Dr. Alan S. Louie

Monetizing Watson - Toy or Game Changer?

By Dr. Alan S. Louie – 4 Comments

Like many, I have watched IBM's Watson computer compete on the answer and question show Jeopardy, wondering what IBM has created.  During the course of the show, my mind regularly wandered off, wondering whether this event has broader implications.  Having been briefed on Watson prior to the show's airing, it is clear that Watson is not HAL (see 2001, A Space Odyssey), and yet, within the confines of the Jeopardy challenge, IBM's innovators have created a skilled Jeopardy competitor second to none


OfflinePhoto of Eric Newmark

While cost reduction across the enterprise is an ongoing focal point for life science companies in the current struggling economy, poorly designed Incentive Compensation Management (ICM) programs can lead to significant revenue opportunities left on the table that far exceed what any corporate cost-reduction effort could provide. After general payroll, incentive compensation can be among a company's largest expenses. Consequently, companies are increasing their focus on incentive compensation and are lookin


OfflinePhoto of Dr. Alan S. Louie

Working Smarter - No Longer An Option

By Dr. Alan S. Louie – 4 Comments

With Pfizer's recent announcement that it is cutting back further on internal R&D and progress on the M&A front (sanofi-Genzyme), the pharmaceutical industry is continuing on its path towards becoming smaller and more agile in the shadow of a fast fading FIPCo business model.  As a term and aspiration prevalent in the 1990's, FIPCo (fully integrated pharmaceutical company) was the aspiration of biotechs and small pharma's alike, as I can attest to as part of Cetus when it built its own manufact



Viewed 687,928 times